The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national ...

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...

National Infertility Awareness Week highlights that infertility impacts both men and women, is more prevalent among Black and ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

Panelists discuss how clinicians should interpret Clinical Dementia Rating-Sum of Boxes (CDR-SB) score changes by correlating ...

A bipartisan letter from lawmakers questions the legality of Robert F. Kennedy Jr's HHS changes and the lack of clear ...

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by ...

The Senate has confirmed Mehmet Oz, MD, to lead CMS, an agency that oversees the health insurance for millions of Americans ...

“The 340B statute does not permit drug companies to unilaterally withhold discounts from 340B hospitals in exchange for the ...